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Cell-based therapies have been in use in veterinary medicine for years. However, 
the legal requirement of manufacturing, placing on the market and use of cell-based 
veterinary pharmaceuticals are not as well developed as the respective requirements 
of chemical pharmaceuticals. Cell-based veterinary pharmaceuticals are medicinal 
products in the sense of the pharmaceutical law of the European Union (EU). For that 
reason, such medicinal products principally require official approval for their manufacture 
and an official marketing authorization for their placement on the market before being 
used by the veterinarian. The manufacture, placing on the market, and use of cell-based 
veterinary pharmaceuticals without manufacturing approval and marketing authorization 
is permitted only in certain exceptional cases determined by EU and individual Member 
State law. Violations of this requirement may have consequences for the respective 
veterinarian under criminal law and under the code of professional conduct in the 
respective Member State. The regular use of cell-based veterinary pharmaceuticals 
within the scope of a therapeutic emergency as well as the import of such veterinary 
pharmaceuticals from non-European countries for use in the EU are currently out of the 
question in the EU because of a lack of legal bases. Here, we review the general legal 
requirement of manufacturing, placing on the market, and use of cell-based veterinary 
pharmaceuticals within the EU and point out different implementations of EU law within 
the different Member States.
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iNtrODUctiON
Cell-based therapies have been available in veterinary medicine for years and are currently expe-
riencing a growing demand. Hereby, they do not only play an import role within the preclinical 
testing of cell-based pharmaceuticals for human use but rather as cell-based therapies for animals 
per  se (1, 2). However, such cell-based therapies can, especially when performable in mammals, 
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serve as an example for the development of respective cell-based 
therapies for human use. This is due to the fact that in general 
“first in animal” studies can be conducted easier than “first 
in man” studies in regard to legal and actual requirements. 
Veterinarians across the European Union (EU) already offer 
such cell-based therapies to their clients and prepare the nec-
essary cell-based therapy products either themselves or obtain 
them from suppliers in their respective member state or from 
abroad. Despite their actual dissemination and meaning, also 
for the development of pharmaceuticals for human use, (stem) 
cell-based pharmaceuticals for veterinary use have been widely 
ignored by legal practice, and no special-law provisions have been 
issued compared to (stem) cell-based pharmaceuticals for human 
use. The existing EU legislation on veterinary medicines is, in 
any case, incomplete and leaves too many loopholes for unproven 
cell-based pharmaceuticals for veterinary use, which then can 
also serve as false examples for the development of cell-based 
pharmaceuticals for human use. Therefore, the current EU and 
national legislations on veterinary medicines need to be reformed 
so as to bring about such legislative and actual improvements, 
which also reflect the meaning of cell-based pharmaceuticals for 
veterinary use for the development of cell-based pharmaceuticals 
for human use.
treAtMeNt MODeLs
Since the first publication of a particular case in 2003, for example 
(3), tendon diseases of horses have been treated with mesenchy-
mal stem cells of various origins, and the cell product or the 
manufacture of the cell product has been offered by a range of 
companies. The first enterprise of this type was VetCell® in Great 
Britain, which offered the treatment of bone marrow samples. The 
attending veterinarian extracts bone marrow, sends it to the com-
pany, which processes it in its laboratory and returns a therapy 
product to the veterinarian that the latter then administers. 
Veterinarians across the EU have been offering their clients such 
therapies as well, by either preparing the necessary cell-based 
therapy products themselves or obtaining them from domestic 
or foreign third parties. Various situations in the preparation and 
use of veterinary pharmaceuticals based on cells are currently 
being observed:
 – Autologous therapies by the veterinarian involving veterinary 
pharmaceuticals prepared by the veterinarian: the attending 
veterinarian extracts samples from the patient (e.g., blood, 
bone marrow, or fat) and processes this material in his medical 
office for the purpose of administering the resulting veterinary 
medicinal product (e.g., cell product) to the same patient.
 – Autologous therapies by the veterinarian involving veterinary 
pharmaceuticals not prepared by the veterinarian: the attend-
ing veterinarian extracts samples from the patient (see above) 
and sends them to a laboratory, which then processes the 
material and sends to the attending veterinarian a veterinary 
medicinal product (e.g., cells in suspension) for administra-
tion to the same patient.
 – Allogenic therapies by the veterinarian involving veterinary 
pharmaceuticals prepared by the veterinarian: the attending 
veterinarian extracts samples from a donor animal (e.g., 
blood, bone marrow, and fat) and processes this material in his 
medical office for the purpose of administering the resulting 
veterinary medicinal product (e.g., cell product) to a recipient 
animal (patient).
 – Allogenic therapies with finished veterinary medicinal prod-
ucts not prepared by the veterinarian: the attending veterinar-
ian obtains a veterinary medicinal product (e.g., cell therapy 
product) from a provider and administers it to his/her patient.
Although in all treatment settings mentioned above the 
cell-based component is at the center of the therapy, there are 
fundamental differences in the legal handling of the individual 
settings. The manufacture, import, and use of cell-based veteri-
nary pharmaceuticals have to comply with EU and respective 
national pharmaceutical law just like other medicinal products. 
Violations of pharmaceutical law may be prosecuted and may 
have consequences under the code of professional conduct for 
the veterinarian (suspension or even loss of medical license) 
where this is provided for in the individual Member State 
legislation. Compared to the human domain, the veterinary 
pharmaceutical law is marked by a more complex principle of 
exceptions to regulations. In addition, there are specific provi-
sions for individual animal species, regulations that do not exist 
in this form with respect to humans. This makes the practical 
manageability of the veterinary pharmaceutical law more dif-
ficult for the legal expert and particularly for the veterinarian 
in practice but does not release them from complying with the 
respective regulations.
cAteGOriZAtiON OF (steM) ceLL-
BAseD ANiMAL tHerAPies UNDer 
PHArMAceUticAL LAW
Cell-based veterinary therapeutics are medicinal products in the 
sense of the pharmaceutical law of the EU (Art. 1 No. 2 Directive 
2001/82/EC) and hereby defined as any substance or combina-
tion of substances presented as having properties for treating or 
preventing disease in animals; or any substance or combination of 
substances, which may be used in or administered to animals with 
a view either to restoring, correcting, or modifying physiological 
functions by exerting a pharmacological, immunological, or 
metabolic action, or to making a medical diagnosis. Whether the 
physiological effect of cell-based forms of therapy results from 
a pharmacological, immunological, or metabolic effect is of no 
consequence since such therapy products, at least in the sense 
of Art. 1 No. 2 Directive 2001/82/EC, are substances or prepara-
tions from substances designated for use in or on the animal body 
and intended as remedies with properties for curing, relieving, 
or preventing diseases or disease symptoms. This eliminates the 
need to resolve the extent to which the cell–cell interactions made 
use of in a (stem) cell-based animal therapy can be attributed to a 
pharmacological, immunological, or metabolic effect. Respective 
definitions can be found within the Medicinal Products Acts 
of the EU Member States, for example, within Sec. 2 German 
Medicinal Products Act.
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(Stem) Cell-based veterinary pharmaceuticals are not, at any 
rate, medical devices in the sense of the directives of EU law 
regarding the definition and regulation of medical devices since 
EU law regarding medical devices only applies to medical devices 
for human use. In other words, there is no specific EU legisla-
tion covering medical devices for veterinary use. This loophole 
in veterinary legislation can therefore lead to doubtful and/
or unproven therapy offers and should be addressed by future 
amendments of veterinary legislation. Furthermore, medicinal 
devices are characterized by the fact that these are items used 
within the scope of a therapeutic application. Substances that 
medicinal products are composed of, by contrast, are spent or 
processed (4). However, the therapeutically administered (stem) 
cells do not permanently remain in or on the animal body 
because, like principally all cells, they have a limited life span 
that is shorter than the life span of the organism as a whole to 
which they are administered. The administered cells therefore 
develop their therapeutic effect during the time between their 
administration and their dissolution brought about, probably 
among others, by cell–cell interactions or by substances released 
by the administered cells. By contrast, a physico-mechanically 
acting therapeutic object principally remains in the body of the 
patient until it is removed (absorbable suture material nonethe-
less is not a medicinal product because its principal intended 
effect is physical rather than specific to a medicinal product, cf. 
Art. 1 para. 2 lit. a) Directive 93/42/EEC). Therefore, therapeuti-
cally used cells constitute consumable substances or substances 
that are processed (see Requirement of Official Authorization 
for (Stem) Cell Isolation), which means that cells can principally 
have the characteristic of a medicinal product.
Furthermore, cell-based forms of therapy in the veterinary sec-
tor are not tissue in the sense of the EU Tissue Directive 2004/23/
EC since that directive lays down standards of quality and safety 
only for human tissues and cells intended for human applications 
in order to ensure a high level of protection of human health (Art. 
1). These special provisions of tissue law must thus not be applied 
to animal tissue used on or in an animal. Additionally, until today, 
there is no specific EU legislation governing cell-based medicinal 
products for veterinary use. However, the EU legislation regard-
ing medicinal products for veterinary use is currently subjected to 
a reform process, which is supposed to cover cell-based medicinal 
products for veterinary use with specific provisions in the future 
(cf. Conclusion and Outlook).
POssiBLe eXcePtiON FrOM 
tHe APPLicAtiON OF 
PHArMAceUticAL LAW
The fact that a product is a medicinal product in the sense of the 
EU pharmaceutical law is not to be confused with the issue of 
whether pharmaceutical law applies. The Community code for 
veterinary pharmaceuticals, Directive 2001/82/EC, first defines 
in Art. 1 No. 2, the substances and substance preparations, which 
are considered veterinary pharmaceuticals. Then, in Art. 2 No. 
1, the Community code stipulates that this Directive shall apply 
(only) to veterinary medicinal products, including pre-mixes for 
medicated feeding stuffs, intended to be placed on the market in 
Member States and prepared industrially or by a method involving 
an industrial process. Since the terms “prepared industrially” and 
“industrial process” have not been defined by EU law or jurisdic-
tion yet, there is no EU-harmonized definition for such processes. 
Therefore, regarding (stem) cell-based veterinary medicinal 
products prepared in-house, i.e., within the practice of the vet-
erinarian, it is unclear what would be the minimum production 
quantity to have an “industrial preparation” and/or an “industrial 
process” in legal terms to cover such in-house preparations by 
the scope of the Community code for veterinary pharmaceuticals. 
However, in the absence of the placing on the market in the sense 
of the Community code for veterinary pharmaceuticals, which 
means that only the manufacturer (e.g., the veterinarian) and its 
directly supervised and bound by instructions staff, but no third 
party such as another independent veterinarian or the owner 
of the respective animal has the power of disposal for the (cell-
based) pharmaceutical, such not placed on the market veterinary 
pharmaceuticals are thus not be governed by the regulations of 
the Community code for veterinary pharmaceuticals in regard 
to an official marketing authorization. As a consequence, there 
is no requirement by the Community code in the Member States 
of the EU to have a marketing authorization for such (cell-based) 
pharmaceuticals produced in-house within the veterinarian’s 
practice. Therefore, the use of in-house prepared pharmaceuticals 
is typically permissible within the EU Member States if nothing 
else is stated within individual Member State law. For example, 
in Germany, such in-house prepared pharmaceuticals for veteri-
nary use do not need a marketing authorization according to the 
German Drug Law. In any case, this exemption from the applica-
bility of the Community code for veterinary pharmaceuticals is 
not equivalent with a statement concerning the therapeutic effect 
of the respective pharmaceutical. However, on the one hand, 
the therapeutic effect of pharmaceuticals that are placed on the 
market is regularly proven by preclinical and clinical trials, on the 
other hand, clinical trials therefore are typically connected to the 
official marketing authorization. Since in-house prepared (cell-
based) pharmaceuticals for veterinary use do not need an official 
marketing authorization, they are also not bound to the legal 
requirements of being tested within clinical trials to examine and 
prove their therapeutic effect under scientific, statistical standards. 
Therefore, until today, claims regarding the therapeutic effect of 
in-house (cell-based) pharmaceuticals should be questioned and 
checked whether they are based on proper clinical trials. In any 
case, the veterinarian is obliged to inform the animal owner about 
this pharmaceutical character of in-house produced (cell-based) 
pharmaceutical to enable the animal owner in the context of an 
informed consent to decide whether he/she wants this kind of 
treatment for the animal and to avoid possible liability risks.
Additionally, one must not confuse the provisions to receive 
a marketing authorization with the additional need to receive 
a manufacturing license for the respective medicinal product. 
Regularly, both the marketing authorization and the manufac-
turing license are mandatory to manufacture and market the 
respective medicinal product. But, within the in-house prepa-
ration settings, there can be additional exceptions regarding 
the need for a manufacturing license. Since the Community 
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code for veterinary pharmaceuticals only applies to veterinary 
medicinal products, including pre-mixes for medicated feeding 
stuffs, intended to be placed on the market in Member States 
and prepared industrially or by a method involving an industrial 
process (cf. above); initially, there is also no requirement by 
the Community code in the EU Member States to connect the 
in-house preparation of such (cell-based) veterinary medici-
nal products to a manufacturing license. However, this only 
concerns (cell-based) veterinary pharmaceuticals prepared and 
administered by the veterinarian himself/herself (cf. Art. 3 para. 
2 lit. a) Directive 2001/82/EC) since these medicinal products 
are not dispensed to third parties. However, these legal require-
ments of the Community code for veterinary pharmaceuticals 
lead to different legislations regarding in-house (cell-based) 
veterinary pharmaceuticals within the Member States of 
the EU. For example, such in-house (cell-based) veterinary 
pharmaceuticals can be prepared and administered without 
a manufacturing and/or marketing authorization license in 
Germany, whereas in other Member States, veterinarians need 
a manufacturing license, which then can also be connected to 
the compliance with the Good Manufacturing Practice (GMP) 
that is among others a matter of additional personnel and 
costs. Therefore, veterinarians are called upon to check their 
individual Member State law regarding the requirements for 
in-house preparing (cell-based) veterinary pharmaceuticals to 
avoid criminal prosecution and/or negative consequences on 
basis of the code of professional conduct where this is provided 
for in the individual Member State legislation.
reQUireMeNt OF OFFiciAL 
AUtHOriZAtiON FOr (steM) 
ceLL isOLAtiON
In any case, placing on the market is planned by the manufacturer 
or takes place actually, i.e., the change in power of disposal for the 
respective (cell-based) pharmaceutical, this has also an effect on 
the initial (stem) cell isolation from the animal. In these cases, 
concerning the manufacture of active substances and/or medici-
nal products in the sense of pharmaceutical law, the biopsy of 
cells and tissue from animals is covered, among others, by Art. 44, 
50 lit. f), 50a Directive 2001/82/EC and thus principally requires 
authorization in the Member States. One reason why the isolation 
of animal cells for therapeutic use in the veterinary sector requires 
official authorization according to Art. 44, 50a Directive 2001/82/
EC, is because the animal cells to be biopsied are active substances 
and not just source or raw material, which can principally be 
obtained without authorization. To be considered as an active 
substance requires that the material in question is a substance 
in the sense of the pharmaceutical law because the term “active 
substance” goes back to the term “substance” used in pharma-
ceutical law and supplements it. Animal (stem) cells fit the term 
“substance” used in pharmaceutical law because, pursuant to Art. 
1 No. 4, 2nd bullet point, Directive 2001/82/EC, they are body 
components of animals, including cells (5). It follows that these 
substances, if additional requirements are fulfilled, are principally 
suited to be or be made into an active substance.
The term “active substance” is not defined for veterinary 
medicinal products within the Community code. But the term 
can be interpreted under legal aspects in compliance with Art. 1 
No. 3a of the Community code for medicinal products for human 
use (Directive 2001/83/EC). Since both directives refer to “active 
substance” and both directives furthermore concern the same 
legal matter, namely, the regulation of the pharmaceutical sector, 
such a comprehensive interpretation is possible. Based on the 
substance concept in pharmaceutical law and with due regard to 
the term “active substance,” an active substance in the sense of the 
pharmaceutical law thus is a substance intended to be used as an 
active pharmaceutical ingredient in the manufacture of (veteri-
nary) medicinal products or to become an active pharmaceutical 
ingredient of the (veterinary) medicinal products when used 
in the manufacture of (veterinary) medicinal products. These 
prerequisites for the term “active substance” do not conflict with 
the possibility that, with respect to animal (as well as human) 
cells, the biopsied animal cells may have to be modified and/or 
cultivated in vitro by cell and tissue cultivation processes before 
being used therapeutically on animals.
If the biopsied animal (stem) cells were used in therapy 
without further processing, these cells would also be an active 
substance in the sense of pharmaceutical law because these 
cells would already be an active pharmaceutical ingredient of a 
medicinal product. Nothing else can then apply to cells processed 
after the biopsy, since the cells to be biopsied are intended, when 
used in the manufacture of pharmaceuticals, to become an active 
pharmaceutical ingredient of the respective medicinal product. 
This is also consistent with the fact that animal organs are not 
considered active substances, if substances are first to be extracted 
from these organs or from the individual cells of these organs 
for later use in the production of medicinal products.1 The key 
difference between acknowledging the property of active sub-
stance with respect to animal cells to be biopsied and denying 
the property of active substance to animal organs lies in the fact 
that the cells that are to be used therapeutically are used as such 
and become part of the finished therapy product, whereas in the 
case of organs, it is only one component that is extracted, while 
the organ as a whole, or the cells in this case, is/are not present 
in the therapeutic product. If the organ were rated to be an active 
substance, then the biopsy of cells for therapeutic use would by 
implication classify the living organism as a whole as an active 
substance.
Manufacturing (of the active substance) means, inter alia, the 
acquisition of an active substance; in the case of cells “acquisition” 
must mean cell removal, i.e., biopsy. Pursuant to Art. 50 lit. f) 
Directive 2001/82/EC the manufacture and thus cell acquisition 
shall be performed under the conditions of GMP. In the assess-
ment of Directive 2001/82/EC, the veterinarian, however, does 
not need an authorization for cell removal, if he/she isolates the 
cells under his/her immediate technical responsibility for the 
purpose of personal application to animals he/she is treating, 
1 So at least even for human organs, so that it can safely be assumed for animal 
organs as well (6), see also Ref. (7), which states that the organ removal does not 
(yet) have to follow GMP conditions.
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since there is no placing on the market involved. It is therefore 
irrelevant whether the treatment regimens are autologous or allo-
genic as long as the same veterinarian is exclusively in power of 
disposition related to the biopsied cells and the in-house prepared 
cell-based pharmaceuticals respective as well as related to the 
administration of this pharmaceutical and as long as this remains 
a non-industrial activity. However, this requirement of the 
Directive has been implemented differently within the Member 
States, i.e., in Germany such in-house preparations do not need 
manufacturing licenses, whereas other Member States require a 
license even for in-house prepared (cell-based) pharmaceuticals, 
which are not placed on the market (cf. Possible Exception from 
the Application of Pharmaceutical Law). In any case, failure to 
comply with the authorization requirement can routinely be 
prosecuted as a criminal and/or administrative offense in the 
respective Member States if a manufacturing license is needed 
in the respective Member State or if individual Member State law 
does not allow in-house medicinal preparation at all.
PrOcessiNG OF ANiMAL (steM) ceLLs 
reQUiriNG AUtHOriZAtiON
Pursuant to Art. 44 para. 1 Directive 2001/82/EC, the manufac-
ture of a (stem) cell-based therapeutic product for the veterinary 
sector constitutes the manufacturing of a (veterinary) pharma-
ceutical, which principally requires authorization. Art. 44, 50 lit. 
f) Directive 2001/82/EC states that the manufacture of veterinary 
medicinal products must comply with the conditions of GMP. 
Here, too, the special provisions of the Tissue Directive 2004/23/
EC of the EU are not applicable in the veterinary sector because 
the Tissue Directive, as stated by its Art. 1, is pertinent only to 
the therapeutic use of human tissues on humans. Responsible for 
issuing the authorization are the authorities within the respective 
Member State, in Germany, for example, the authorities of the 
federal state in which the manufacture actually is to take place.
With respect to the manufacture of a cell-based veterinary 
pharmaceutical, the veterinarian also does not need an official 
authorization in the sense of the Art. 44, 50 lit. f) Directive 
2001/82/EC for the preparation in autologous and allogenic 
treatment regimens, if he/she processes the previously removed 
cells under his/her immediate technical responsibility for the 
purposes of the treatment he/she is performing (cf. Art. 3 para. 
2 lit. a Directive 2001/82/EC) as long as the same veterinarian is 
exclusively in power of disposition related to the biopsied cells 
and the in-house prepared cell-based pharmaceuticals respective 
as well as related to the administration of this pharmaceutical and 
as long as this remains a non-industrial activity. If, in a given case, 
the veterinarian removes (stem) cells from an animal and pro-
cesses these cells and then administers these cells to an animal, 
an official authorization is not needed, as stated in Art. 44, 50 lit. 
f) Directive 2001/82/EC. However, this requirement of the EU 
Directive 2001/82/EC has been implemented differently within 
the Member States, so that in some states such as Germany, no 
license is necessary for the treating veterinarian to prepare such 
cell-based pharmaceuticals in-house, whereas in other member 
states (cf., for example, legal situation in Belgium), the treating 
veterinarian is not allowed to prepare his own medicinal product. 
In any case, conversely it also means that the veterinarian does 
need such an authorization, if he/she removes and processes the 
cells and then releases the cells from his/her veterinary area of 
delegation. Failure to comply with the authorization require-
ment regarding the manufacture of medicinal products can be 
routinely prosecuted in the Member States where this is provided 
for in the individual Member State legislation. For example, in 
Germany, violations can be punished under Section 96 No. 4 
German Medicinal Products Act by imprisonment of up to 1 year 
or by a fine.
MArKetiNG AUtHOriZAtiON 
reQUireMeNt FOr (steM) ceLL-BAseD 
veteriNArY PHArMAceUticALs
As veterinary pharmaceuticals in the sense of Art. 1 No. 2 
Directive 2001/82/EC, veterinary pharmaceuticals in the EU 
principally require marketing authorization as per Art. 5 para. 1 
Directive 2001/82/EC. In the absence of marketing authorization, 
the veterinary pharmaceutical may not be placed on the market. 
Since the veterinary pharmaceutical law is harmonized within the 
EU law by Directive 2001/82/EC (Community code for veteri-
nary pharmaceuticals), this requirement is applicable in all EU 
Member States. There are various legally named exemptions from 
the marketing authorization requirement. Such legally named 
exemptions are not to be confused with the abovementioned (cf. 
Possible Exception from the Application of Pharmaceutical Law) 
questions of the general applicability of the Community code for 
veterinary pharmaceuticals due to missing industrial preparation/
industrial processes and/or the missing placing on the market in 
legal terms. If, however, such a legally named exemption exists, 
the respective veterinary pharmaceutical can be placed on the 
market and used without official marketing authorization. In the 
assessment of Art. 3 para. 2 Directive 2001/82/EC that applies, 
among others, to veterinary pharmaceuticals produced in phar-
macies for individual animals or animals of a particular holding. 
However, in accord with the assessments of the regulations 
regarding a therapeutic emergency (see below), this exemption 
may only be claimed if, among others, an authorized medicinal 
product is not available for the respective animal species or the 
respective field of application and if the required medical care 
of the animals would otherwise be seriously jeopardized. The 
efficacy of cell-based pharmaceuticals in the veterinary sector 
still needs to be demonstrated and currently available authorized 
medicinal products ensure medical care of most patients to a 
great extent. Therefore, regarding cell-based pharmaceuticals, 
therapeutic emergency should currently be questioned and only 
applied when thoroughly investigated and justified. This situation 
may change, however, depending on clinically proven indications 
for the therapeutic use of cell-based products. In any case, a vet-
erinarian may use an alternative yet unproven cell-based therapy 
only in case (conservative) registered therapies are verifiably 
ineffective.
An additional exemption from the marketing authorization 
requirement can arise within the scope of cell-based on-site 
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treatment regimens. According to the assessment of Art. 2 para.1; 
3 para. 2 Directive 2001/82/EC, the marketing authorization 
requirement concerns only medicinal products placed on the 
market. Without placement on the market, there can be no 
requirement of marketing authorization. But a placement on the 
market does not exist when the veterinarian uses the veterinary 
pharmaceutical in question on an animal. What is missing for the 
placement on the market is the concession of the power of control 
over the pharmaceutical concerned to third parties apart from the 
veterinarian (8–10).2 With respect to cell-based veterinary phar-
maceuticals, the veterinarian therefore – in autologous as well 
as in allogenic treatment models – has to remove the cells him/
herself (within the scope of his/her veterinary freedom of delega-
tion), process them him/herself, if applicable, and then use them 
him/herself on the animal in order not to require authorization 
under pharmaceutical law and marketing authorization for these 
activities. This does therefore also mean that cell-based veterinary 
pharmaceuticals not prepared by the veterinarian him/herself, 
i.e., which the veterinarian acquires from third parties, princi-
pally require marketing authorization regardless of whether they 
were obtained in Germany or abroad. Therefore, the outsourc-
ing of the preparation of the (stem) cell-based pharmaceutical 
after the biopsy from the veterinarian’s practices to a third-party 
manufacturer can only be in compliance with the requirements of 
EU pharmaceutical law, if the third-party manufacturer holds an 
official manufacturing license according to EU law. Additionally, 
the veterinarian needs a license for the biopsy itself, if she/he sup-
plies a third party with cells to manufacture a cell-based medici-
nal product (cf. Requirement of Official Authorization for (Stem) 
Cell Isolation). The license for the veterinarian is mandatory, to 
ensure compliance with the GMP standard. This supplying action 
of the veterinarian is therefore different from the situation, when 
the veterinarian just takes a biopsy to analyze the cells within a 
diagnostic procedure. The veterinarian does not need an extra 
license for such diagnostic related biopsies.
cOMPeteNce FOr MArKetiNG 
AUtHOriZAtiON
Which authority is competent for authorizing the marketing of a 
veterinary pharmaceutical depends on the type of actual veteri-
nary pharmaceutical. The European Commission, for example, 
advised beforehand by the European Medicines Agency (EMA), 
is competent under the terms of Art. 3 para. 1 Regulation (EC) 
No. 726/2004 for issuing the marketing authorization for vet-
erinary medicinal products manufactured by certain biotechno-
logical methods. Veterinary medicinal products manufactured, 
among others, by recombinant DNA technology or processes 
of the controlled expression of genes coding for biologically 
active proteins in prokaryotes and eukaryotes, including trans-
formed mammalian cells, therefore have to receive mandatory 
2 All citations relative to medicinal products for human use. But there can be no 
legal difference for veterinary medicinal products since the terms “dispensing/plac-
ing on the market” are treated identically for medicinal products for veterinary and 
for human use at least within the German Medicinal Products Act.
centralized marketing authorization from the Commission. If 
neither of these techniques is applied and if the treatment does 
not serve to improve agro-technical performance, for example, 
the marketing authorization procedure of the respective Member 
State is applicable. Relevant in Germany is the procedure as per 
Section 21 German Medicinal Products Act. The competent 
agency for the marketing authorization of such cell-based vet-
erinary pharmaceuticals thus is – under the terms of Section 77 
para. 3 German Medicinal Products Act – the Federal Office for 
Consumer Protection and Food Safety (BVL).
PrescriPtiON reQUireMeNt FOr 
ceLL-BAseD veteriNArY 
tHerAPeUtic PrODUcts
Cell-based veterinary pharmaceuticals are subjected to medical 
prescription. One reason why the classification of cell-based 
veterinary pharmaceuticals as prescription (veterinary) phar-
maceuticals is of significance under legal aspects is the fact that 
violations with respect to the use or marketing of prescription 
pharmaceuticals entail stiffer penalties than those involving non-
prescription pharmaceuticals.
Within the EU, the prescription requirement for cell-based 
veterinary pharmaceuticals follows from Art. 67 lit. c) Directive 
2011/82/EC. It makes veterinary pharmaceuticals available by 
veterinary prescription only if, among others, the product is 
intended for the treatment of diseases that require prior exact 
diagnosis or if its use may have consequences that would ham-
per or interfere with the subsequent diagnostic or therapeutic 
measures. The stem cell therapy of a horse’s tendon disease, 
for example, always involves veterinary diagnostics (clinical 
diagnostics, ultrasound diagnostics) that are necessary in any 
case to determine the localization, the extent and the age of 
the damage in order to be able to establish a specific therapy 
plan and to administer the cell therapy product pointedly and 
effectively.
ceLL-BAseD PHArMAceUticALs NOt 
tO Be UseD iN NON-FOOD-PrODUciNG 
ANiMALs WitHiN tHe scOPe OF A 
tHerAPeUtic eMerGeNcY
The provisions regarding the use of pharmaceuticals within the 
scope of a therapeutic emergency have been harmonized within 
the EU by Directive 2001/82/EC and currently leave no room for 
the use of cell-based pharmaceuticals in the veterinary sector. 
In a given case, the veterinarian may administer, dispense, or 
prescribe medicinal products under Art. 10 Directive 2001/82/
EC that have not been authorized for the respective therapeutic 
indication and/or respective animal species, if the medical care 
of the animal to be treated would otherwise be jeopardized 
and a direct or indirect threat to the health of humans and 
animals is not to be feared. But the justification for these exemp-
tions stated here remains to be demonstrated (cf. Marketing 
Authorization Requirement for (Stem) Cell-Based Veterinary 
Pharmaceuticals).
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Art. 10 lit. a) Directive 2001/82/EC permits the treatment 
of the animal in question only with a (cell-based) veterinary 
pharmaceutical that is authorized in the respective Member State 
for another therapeutic indication or for another animal species. 
However, such cell-based veterinary pharmaceuticals do (cur-
rently) not exist in Germany. Even if they existed, it is doubtful 
whether the necessary medical care of the animals would be seri-
ously jeopardized without their use (see above). Without such a 
hazard, however, the use in the sense of Art. 10 Directive 2001/82/
EC is not admissible. In the example of the sinew therapy, a purely 
conservative therapy could be used instead of the cell therapy. 
While it might not have the same optimized therapeutic effect, 
this approach would hardly pose a serious risk to the patient. 
In general, only in case (conservative) registered therapies are 
ineffective, a veterinarian may use an alternative unproven (cell-
based) therapy, whereas he/she is obliged to inform the owner of 
the animal about the scientific status of the respective unproven 
pharmaceutical to avoid the risk of liability.
Based on the exception stipulated in Art. 10 lit. b) Directive 
2001/82/EC, medicinal products authorized for human use and 
(other) medicinal products authorized in a Member State of 
the EU or another signatory of the Agreement on the European 
Economic Area for use on animals can also be prescribed, admin-
istered, or dispensed to animals within the scope of a therapeutic 
emergency in the veterinary sector. In the area of cell-based types 
of therapy, for example, it would be conceivable that a respective 
cell-based pharmaceutical authorized for the treatment of carti-
lage defects of humans (such marketing authorizations exist) is 
used to treat the joint disorder of a dog. This is another case where 
the optimized treatment of the dog could possibly be compro-
mised if it did not include the use of cell-based pharmaceutical 
for human use, but the animal would most likely not be seriously 
harmed.
Finally, according to Art. 10 lit. c) Directive 2001/82/EC, the 
veterinarian may, as an exception, treat the animal concerned 
with a veterinary medicinal product prepared extemporaneously 
by a person authorized to do so under national legislation in 
accordance with the terms of a veterinary prescription.
The manufacture of such cell-based prescription pharmaceu-
ticals for animals will fail not least for practical reasons. While 
pharmacies are commonly authorized to prepare (veterinary) 
medicinal products, they are just as commonly technically 
unequipped to prepare such cell-based veterinary medicinal 
products. However, the exception also requires that the medical 
care of the animals be in serious jeopardy without such a prescrip-
tion pharmaceutical. Depending on national law, the veterinarian 
may possibly be authorized to prepare such cell-based veterinary 
pharmaceuticals. In Germany, for example, this is permitted only 
to a limited extent. The preparation of a cell-based veterinary 
pharmaceutical by a veterinarian would only be an option, 
according to Section 56a para. 2 No. 4; Section 13 para. 2 Sentence 
1 No. 3 lit. d) German Medicinal Products Act, if an authorized 
cell-based finished medicinal product existed from which the 
veterinarian in his/her veterinary dispensary would prepare a 
(new) medicinal product, possibly with the use of non-active 
pharmaceutical ingredients. The veterinarian thus first has to 
examine again whether, without the manufacture and use of a 
medicinal product manufactured and administered this way by 
the veterinarian the medical care of the concrete animal would 
be seriously compromised. Only then can a manufacture and use 
even be considered. If that is the case, the veterinarian then has 
to check whether such authorized cell-based finished medicinal 
products exist. For the veterinary sector, this is currently not the 
case, but individual cell-based medicinal products for human use 
have already been authorized.
It is important to note that in all Member States of the EU the 
veterinarian is not free to select a particular regulation from among 
the abovementioned exceptions of Art. 10 Directive 2001/82/EC 
that can be found in the legal systems of the respective Member 
States; instead, he/she has to follow the therapy cascade of Art. 10 
stipulated by the law itself, which means examining first whether 
the exception as per Art. 10 lit. a) is pertinent. Only if this is not 
the case, he/she may resort to the regulation of Art. 10 lit. b). If 
this is not met either, he/she may use medicinal products as per 
Art. 10 lit. c).
Violations of the requirements of pharmaceutical law with 
respect to the handling of prescription veterinary pharmaceuti-
cals in a therapeutic emergency are commonly prosecuted under 
national criminal law where this is provided for in the individual 
Member State legislation as it is in Germany.
NO sPeciFic reGULAtiONs FOr  
NON-FOOD-PrODUciNG eQUiDAe
The use of cell-based veterinary pharmaceuticals in Equidae 
follows the provisions pertaining to classical medicinal products 
for use in non-food-producing Equidae. This means that such 
Equidae may be treated with any medicinal product, including a 
cell-based veterinary pharmaceutical, as long as this is in compli-
ance with the remaining provisions of pharmaceutical law (11).
iMPOrt OF ceLL-BAseD veteriNArY 
PHArMAceUticALs iNtO tHe 
eUrOPeAN UNiON
According to the assessment of Art. 44 para. 3 Directive 2001/82/
EC, the import of (cell-based) veterinary pharmaceuticals into the 
EU from countries that are not members of the EU is subjected 
to an official authorization. The competence for issuing such an 
authorization follows from the legal provisions of the country 
into which the (cell-based) veterinary pharmaceutical is to be 
imported as well as from EU provisions. The import license is 
limited to the respective country and not to be confused with the 
regular marketing authorization of a veterinary pharmaceutical 
under pharmaceutical law. As a rule, such an import license is 
linked to the condition that no authorized pharmaceutical is on 
the market within the EU for the respective animal species and/
or indication.
When importing animal cells – regardless of their pharmaceu-
tical nature – from non-EU Member States into the EU, caution 
is generally advised. Animal cells can principally not be imported 
freely into the EU. There are specific import regulations, such 
as EU (EC) Regulations No. 1069/2009 or No. 142/2011, to be 
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observed. The purpose of these regulations is, among others, to 
avoid the spreading of animal epidemics within the EU.
crOss-BOrDer MOveMeNt OF ceLL-
BAseD veteriNArY 
PHArMAceUticALs WitHiN tHe 
eUrOPeAN UNiON
In a Member State of the EU, a (cell-based) veterinary pharma-
ceutical may only be placed on the market – as stipulated in Art. 
5 para. 1 Directive 2001/82/EC – if a marketing authorization has 
been granted by the competent authorities of that Member State 
in accordance with this Directive, or if a marketing authoriza-
tion has been granted in accordance with Regulation (EC) No. 
726/2004. Only those veterinary pharmaceuticals placed on the 
market in accordance with Regulation (EC) No. 726/2004, i.e., 
those authorized centrally by the EU, may be transferred across 
borders within the EU without further Member State authoriza-
tion. If the respective (cell-based) veterinary pharmaceutical, 
however, is on the market in a Member State under a Member 
State authorization, it is permitted to be on the market only in that 
Member State. The transfer of such a veterinary pharmaceutical 
from the Member State in which its marketing is authorized into 
Member State in which its marketing is not authorized is then 
governed by the legal provisions of the country into which the 
pharmaceutical is to be transferred.
In case of violations of the authorization and marketing 
authorization requirements, the veterinarian cannot claim to 
have been unaware of these requirements. Basic knowledge 
of whether the pharmaceuticals he/she uses conform to 
authorization requirements is one of the core competences of 
a practicing veterinarian. If the veterinarian is uncertain about 
the conformity to authorization requirements, he/she can be 
expected to inform him/herself of the authorization status of 
a specific pharmaceutical before using it. Violations of require-
ments under pharmaceutical law and thus under the codes of 
professional conduct of veterinarians can cast doubt on the 
reliability of the veterinarian and thus the legitimacy of his/
her medical license where this is provided for in the individual 
Member State legislation.
ceLL tHerAPY PrODUcts FOr  
FOOD-PrODUciNG ANiMALs
To ensure the quality of the food and its safety for human 
consumption, the use of medicinal products in food-producing 
animals is subjected to more stringent requirements than the use 
of medicinal products in non-food-producing animals (cf. Art. 6 
and 66 para. 3 Directive 2001/82/EC). This principle thus has to 
apply to cell-based veterinary pharmaceuticals as well, regardless 
of whether such cell-based veterinary medicinal products are 
marketed in the sense of pharmaceutical law or are veterinary 
pharmaceuticals manufactured individually by veterinarians. 
The important factor is the use of the pharmaceutical. The 
only medicinal products permitted to be used in food-pro-
ducing animals are those that have either undergone a positive 
residue assessment [cf. Art. 6 Directive 2001/82/EC as well as EU 
Regulation (EC) No. 37/2010] or out-of-scope-substances within 
the meaning of Regulation [(EC) 470/2009], which are exempted 
from the requirement of a residue assessment. Out-of-scope-
substances are substances or their residues, which do not pose 
danger to the health of the consumer on the basis of currently 
known facts. Although such residue assessments do not yet exist 
for cell-based veterinary pharmaceuticals, stem cells in general 
are meanwhile listed as out-of-scope. Therefore, at least stem 
cells can be used within autologous and allogenic treatments 
for food-producing animals. It has not yet been finally clarified 
whether this out-of-scope requirement regarding stem cells also 
includes differentiated cells (e.g., chondrocytes either biopsied 
themselves and then transplanted or differentiated from stem 
cell). In any case, the out-of-scope requirements only exempts 
from the residue assessment, but not from the requirement for 
the market authorization.
ceLL tHerAPY PrODUcts FOr  
FOOD-PrODUciNG eQUiDAe
The exceptions applying to food-producing Equidae differ from 
those for other food-producing animals, as stipulated in Art. 10 
para. 3 Directive 2001/82/EC. First, unless otherwise specified 
in the horse passport, Equidae may be treated with medicinal 
products that may be administered to other food-producing ani-
mals as well. Second, food-producing Equidae may additionally 
be treated with certain medicinal products that are not listed in 
the appendix of Regulation (EC) No. 37/2010 and consequently 
do not require a residue assessment. This presupposes, however, 
that such medicinal products contain substances, which EU 
Regulation No. 1950/2006 [in current version following modi-
fications by Regulation (EU) Nr. 122/2013], in accordance with 
Directive 2001/82/EC (Art. 10 para. 3), lists as substances that 
are essential for the treatment of Equidae. But these so-called 
whitelists so far do not contain any cell-based pharmaceuticals 
either, making the use of cell-based pharmaceuticals incompatible 
with the status of a food-producing animal. However, since stem 
cells have already out-of-scope status according to Regulation 
(EC) 470/2009 for food-producing animals in general, stem cells 
can also be used to treat food-producing Equidae; inasmuch 
as such stem cell-based medicinal products are in compliance 
with the further pharmaceutical legislation, e.g., the requirement 
for market authorization (cf. Cell Therapy Products for Food-
Producing Animals).
ADDitiONAL PrOBLeM: Use OF 
GeNetic eNGiNeeriNG PrOcesses 
FOr veteriNArY PHArMAceUticALs 
tHAt HAve NOt BeeN AUtHOriZeD 
UNDer PHArMAceUticAL LAW
The use of cell-based veterinary pharmaceuticals containing 
genetically modified organisms (GMOs) in the sense of the 
European genetic engineering law in an animal may entail 
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additional legal requirements under the genetic engineering law. 
Regarding cell-based veterinary pharmaceuticals, the require-
ments of Release Directive 2001/18/EC and of System Directive 
2009/41/EC or their acts of transposition in the respective Member 
States may be of significance. The System Directive regulates the 
handling of GMOs within genetic engineering facilities such as 
laboratories. The Release Directive specifies, among others, the 
legal conditions for field tests and certain types of marketing of 
GMOs.
The applicability of the Genetic Engineering Act to the field 
of veterinary therapy further ensues from the fact that the ani-
mal treated with the genetically modified cells becomes itself a 
genetically modified (whole) organism in the sense of the Genetic 
Engineering Act by the transfer of these cells. This legal assess-
ment follows from Art. 2 No. 2 Sentence 1 Directive 2001/18/EC 
regarding the definition of “genetically modified organism” and 
from Art. 2 Sentence 2 No. 2 lit. a); Annex I A, Part 1 Directive 
2001/18/EC regarding the definition of genetic modification 
techniques.
Art. 2 Sentence 2 No. 2 lit. a); Annex I A, Part 1 Directive 
2001/18/EC contains a non-exhaustive – “inter alia” – list of 
genetic modification techniques in the sense of the Genetic 
Engineering Act. This means that under legal aspects the creation 
of a GMO can also occur, if the specific technique is not explicitly 
mentioned in the law, but if the assessment made by the law in 
the specific cases given can also be applied to unmentioned 
techniques. According to Nos. 1, 2 Annex I A, Part 1 concerning 
Art. 2 Sentence 2 No. 2 lit. a) Directive 2001/18/EC, techniques by 
which genetic material produced outside the organism and thus 
not naturally occurring in this organism is inserted into an organ-
ism that has not been genetically modified, are considered genetic 
modifications, so that the organism into which this non-natural 
genetic material is inserted is regarded as a GMO. In addition, 
No. 3 Annex I A, Part 1 concerning Art. 2 Sentence 2 No. 2 lit. 
a) Directive 2001/18/EC classifies the fusion of a genetically 
modified cell (=GMO as per Art. 2 No. 2 Sentence 1 Directive 
2001/18/EC) with a naturally occurring cell as the formation of 
a genetically modified (whole) organism. If therefore even one 
genetically modified cell is transferred to a genetically not modi-
fied animal (=organism in the sense of the Genetic Engineering 
Act), the animal is regarded as a genetically modified (whole) 
organism after that transfer. It cannot be ruled out in this case 
that the modified genetic information of the transferred cell may 
also pass entirely or partially to other cells of the animal after 
the transfer. Nor is the transfer of genetically modified cells to a 
genetically not modified organism therefore of a different qual-
ity, under the aspect of genetic modification, than the fusion of 
a genetically modified cell with a genetically not modified cell, 
a technique regarded as genetic modification according to Nos. 
1, 2 Annex I A, Part 1 concerning Art. 2 Sentence 2 No. 2 lit. a) 
Directive 2001/18/EC.
Art. 5 Directive 2001/18/EC finally regulates the release 
and marketing of GMOs and of products containing GMOs 
or components thereof. Since an animal treated with geneti-
cally modified cells is itself a GMO in the sense of the Genetic 
Engineering Act, the release of such an animal from the genetic 
engineering facility (Art. 4 para. 1, Art. 5 ff. Directive 2001/18/
EC) as well as the marketing (=transfer to third parties, as in 
the case of release from the veterinarian’s office and transfer to 
the animal’s owner) (Art. 4 para. 1, Art. 12 ff. Directive 2001/18/
EC) would require authorization. Besides, the veterinarian who 
wishes to prepare and/or use genetically modified cells would 
have to maintain a genetic engineering facility in the sense of 
the genetic engineering law (cf. Art. 1 Directive 2001/18/EC) 
that would have to be officially reported or registered, depend-
ing on the genetic engineering performed, which could require 
authorization itself.
The same applies if the veterinarian wants to market merely 
the genetically modified cells needed for autologous or allogenic 
treatment models. This is rated as the marketing of products 
containing or consisting of GMOs, which is subjected to 
authorization under Art. 4 para. 1, Art. 12 ff. Directive 2001/18/
EC. Aside from this authorization requirement pursuant to the 
Genetic Engineering Act, such actions would probably result in 
veterinary pharmaceuticals that require marketing authorization 
because the cells concerned would be marketed in the sense of 
the pharmaceutical law.
Violations of the requirement to obtain authorization for the 
operation of a genetic engineering facility and violations relative 
to a release can be prosecuted under national law where this is 
provided for in the individual Member State legislation as it is, for 
example, within the German Genetic Engineering Act and with 
the German Criminal Code.
cONcLUsiON AND OUtLOOK
Techniques of regenerative medicine, such as cell-based tech-
niques or the use of cell-free preparations made from blood 
or bone marrow, take the therapeutic efforts of veterinarians 
to new dimensions and are therefore sought after and put to 
use (1, 2). In any case, the practice of sending tissue such as 
bone marrow, fat, or blood as well as (stem) cells to a labora-
tory to get a usable product in return, or of acquiring finished 
products from national or even international suppliers is a legal 
minefield for the veterinarian, in as much as it is unclear for 
the veterinarian whether the third-party manufacturer holds an 
official EU law compliant manufacturing license. It is necessary, 
however, to create legal provisions that will help solve this unsat-
isfactory condition. Veterinary pharmaceutical law is currently 
being reformed on the European level. In its position paper of 
July 15, 2010 (12), the EMA stated that cell-based veterinary 
pharmaceuticals as the so-called advanced therapy veterinary 
medicinal products are not yet covered by the EU code for 
veterinary pharmaceuticals (Directive 2001/82/EC). There is 
a need, however, for a uniform legal framework throughout 
the EU for such advanced therapy veterinary pharmaceuticals, 
similar to the ATMP regulation on advanced therapies, which 
apply to advanced therapy pharmaceuticals for human use. This 
idea is also taken up by the “Proposal for a Regulation of the 
European Parliament and of the Council on veterinary medicinal 
products, COM(2014)558 final” prepared in September 2014. 
According to Art. 38 No. 2 lit. d) of the proposed regulation, 
biological veterinary pharmaceuticals containing or consisting 
of artificially produced allogenic tissue or cells would then have 
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to be authorized centrally by the EU. Only those veterinary 
pharmaceuticals containing autologous or allogenic cells or 
tissue that were not subjected to any industrial process would 
not have to be centrally authorized by the EU, according to Art. 
2 para. 4 lit. b) of the proposed regulation. This raises the further 
question, though, whether they need to be authorized by the 
individual Member States before being permitted to be placed 
on the market. Finally, it is to be welcomed that in 2014 the EMA 
has established the “Ad Hoc Expert Group on Veterinary Novel 
Therapies” (ADVENT) to provide advice to the Committee for 
Medicinal Products for Veterinary Use (CVMP) within the EMA 
(13). Since the concepts of cell-based therapies in veterinary as 
well as in the human sector are novel therapies compared to 
classically chemical pharmaceuticals, the ADVENT will also 
work on cell-based therapies for veterinary use (14).
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